Table 3 Baseline characteristics of the CHC patients before anti-HCV treatment after propensity score matching.
Parameters | SVR (+) (N = 99) | SVR (−) (N = 99) | P - valuea SVR(+) vs. SVR(−) |
|---|---|---|---|
Male | 46(46.5%) | 44(44.4%) | 0.775 |
Age, years | 47(41–57) | 49(40–56) | 0.860 |
Genotype | |||
1 | 59(59.6%) | 67(67.6%) | 0.134 |
2 | 7(7%) | 2(2%) | |
3 | 12(12.1%) | 7(7%) | |
Others and unknown | 21(21.2%) | 23(23.2%) | |
HCV-RNA, log IU/mL | 5.84(4.66–6.66) | 6.19(4.64–6.64) | 0.456 |
FPG, mmol/L | 5.35(4.99–5.98) | 5.33(5.02–5.83) | 0.900 |
Prediabetes | 21(21.2%) | 27(27.2%) | 0.285 |
Diabetes | 10(10.1%) | 7(7.1%) | |
TBiL, umol/L | 15.1(11.2–21.2) | 15.6(10.9–21.4) | 0.948 |
ALT, IU/L | 54(29–97) | 47(27–84) | 0.432 |
AST, IU/L | 42(31–74) | 42(30–76) | 0.934 |
ALB, g/L | 44.4(41.3–46.8) | 43.2(40.80–45.4) | 0.045b |
ALP, IU/L | 83(68–106) | 86(71–105) | 0.541 |
GGT, IU/L | 36(24–67) | 38(20–78) | 0.954 |
Hb, g/L | 142(125–153) | 131(111–142) | 0.001b |
PLTs, 109/L | 128(96–172) | 111(72–157) | 0.094 |
WBCs, 109/L | 5.24(4.14–6.9) | 4.35(3.46–5.67) | 0.001b |
APRI | 0.91(0.55–1.63) | 1.17(0.55–2.21) | 0.326 |
FIB-4 | 2.33(1.52–4.13) | 2.69(1.73–5.33) | 0.181 |
